Utilization and Safety of Trastuzumab Emtansine (T-DM1): a Nationwide Population-Based Study Using the French National Health Data System
ESMO Real World Data and Digital Oncology（2024）
EPI-PHARE | Cancer Survivorship Program - INSERM Unit 981 Molecular Predictors and New Targets in Oncology - Gustave Roussy
Abstract
BackgroundTrastuzumab emtansine (T-DM1), the first antibody–drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has provided new alternatives for metastatic breast cancer (mBC) treatment, and for early-stage breast cancer (esBC) since 2020. We characterized T-DM1 users and assessed the risk of hospitalisation for certain adverse events.Materials and methodsUsing data from the French National Health Data System (SNDS), we identified patients receiving T-DM1 from 2014 to 2022. Sociodemographic data, medical history, and overall survival were described by indication. The risk of adverse event-related hospitalisation was quantified.ResultsWe included 12 822 patients initiating T-DM1 treatment in the study: 9232 (72%) with mBC (median age: 59 years, 54.6% with at least one comorbid condition) and 3590 (28%) with esBC (median age: 54 years, 33.9% with at least one comorbid condition). In mBC, median overall survival was 32.6 months, showing a gradual improvement over the years. At 1 year, 75.8% of patients had discontinued treatment and 22.0% had died. Patients in the study faced higher hospitalisation risks than those with incident breast cancer, with increases of 5.7 and 10.5 times for thrombocytopenia, 3.0 and 4.5 times for interstitial lung disease, 3.3 and 5.9 times for acute liver injury, and 2.3 and 7.3 times for sepsis, for esBC and mBC, respectively.ConclusionsReal-world T-DM1 users frequently present with comorbid conditions and prior treatments, with a higher risk of hospitalisation for severe toxicity events than the general population of incident breast cancers. This study highlights the importance of monitoring treated patients to manage the risk of toxicity and prevent treatment discontinuation.
MoreTranslated text
Key words
trastuzumab emtansine,metastatic breast cancer,early-stage breast cancer,overall survival,adverse event,real-world data
求助PDF
上传PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper